ANDA 208107, held by Watson Laboratories. Amantadine Hydrochloride.
As of Nov 21, 2026, ANDA 208107 (Amantadine Hydrochloride), held by Watson Laboratories, was first approved by FDA on Dec 6, 2016, with 2 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 6, 2016 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Amantadine Hydrochloride100MG · capsule;oral | Amantadine Hydrochloride | Discontinued |
| Jul 10, 2025 | Supplement 4Labeling · Standard review | Approved | None posted |
| Jun 22, 2017 | Supplement 2Manufacturing | Approved | None posted |
| Dec 6, 2016 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters